With a big data-based platform technology that promises to circumvent some of the major challenges of developing and manufacturing cell therapies, Mogrify Ltd. emerged from stealth mode earlier this year. It recently completed a $16m initial close of its series A financing round which brought its total funding to date to just over $20m. It boasts Jane Osbourn, former VP, R&D at AstraZeneca PLC’s MedImmune LLC, as its chair, and Darrin Disley, former CEO of gene editing firm Horizon Discovery Group PLC, as its CEO.
Disley grew Horizon from a start-up in 2007 through IPO in 2014 to the £85m acquisition of Dharmacon from General Electric in 2017, before departing the company in February 2018, by which time it had a market capitalization of around £300m
Mogrify At A Glance
Location: Cambridge, UK
R&D Focus: Cell therapy
Disease Area(s): Diverse
Founding Date: Incorporated in 2016, commercially active from February 2019
Founders: Julian Gough (MRC Laboratory of Molecular Biology, UK), Owen Rackham (Duke-NUS Medical School, Singapore), Jose Polo (Monash University, Australia)
Employees: 35 (and recruiting another 30 in 2019/2020)
